Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell Model [PDF]
Current OncologyAdrenocortical carcinoma (ACC) is a rare and aggressive cancer with limited treatment options, commonly managed with mitotane, which can cause serious side effects, including central hypothyroidism and dyslipidemia.
Irene Tizianel +9 more
doaj +2 more sources
Case Report: Low-dose mitotane in a case of recurrent adrenocortical carcinoma: a 20-year clinical perspective [PDF]
Frontiers in OncologyAdrenocortical carcinoma (ACC) is a rare malignancy with a high risk of recurrence, and the prolonged use of mitotane is often limited by its narrow therapeutic window and endocrine and gastrointestinal toxicity.
Tomasz Buczek +3 more
doaj +2 more sources
Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma [PDF]
Endocrine OncologyObjective: Mitotane is an effective treatment for advanced adrenocortical carcinoma (ACC). Given the limited pediatric data available, this study aims to evaluate the associations between mitotane dosage, plasma drug levels, and anthropometric ...
Maria Riedmeier +28 more
doaj +2 more sources
Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study [PDF]
Endocrine OncologyObjective: Mitotane is the standard therapy for advanced pediatric adrenocortical carcinoma (pACC). With improving survival, treatment-related long-term side effects and their impact on everyday functioning are becoming increasingly relevant.
Heidi Frey +17 more
doaj +2 more sources
Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Mitotane is an adrenolytic drug that exhibits therapeutic effects within a narrow target range (14–20 μg/dL). Various complications develop if the upper limit is exceeded.
You Joung Heo +9 more
doaj +1 more source
Frontiers in Oncology, 2022 Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized.
Xin Liu +20 more
doaj +1 more source
IJU Case Reports, 2022 Introduction The prognosis of patients with unresectable adrenocortical carcinoma is poor. Mitotane is the first‐line treatment for this disease, and etoposide/doxorubicin/cisplatin/mitotane therapy is recommended as first‐line chemotherapy in ...
Yuki Kobayakawa +8 more
doaj +1 more source
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. [PDF]
PLoS ONE, 2018 Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity. The aim of this study was to assess the role of CYP11B1 on mitotane action and metabolism in H295R ACC
Antonina Germano +7 more
doaj +1 more source
EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
Discover Oncology, 2022 Adrenocortical carcinoma affects one in 5 million children each year. Since prognosis for children older than 4 years is limited, clinicians often choose aggressive treatment with etoposide, doxorubicin, cisplatin (EDP) and mitotane after resection ...
Rebecca V. Steenaard +4 more
doaj +1 more source
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
Endocrine Oncology, 2023 Background: This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane.
Nadia Gagnon +7 more
doaj +1 more source